JP7181886B2 - 免疫グロブリンのＦｃ部分を含む二重標的融合タンパク質 - Google Patents

免疫グロブリンのＦｃ部分を含む二重標的融合タンパク質 Download PDF

Info

Publication number
JP7181886B2
JP7181886B2 JP2019549510A JP2019549510A JP7181886B2 JP 7181886 B2 JP7181886 B2 JP 7181886B2 JP 2019549510 A JP2019549510 A JP 2019549510A JP 2019549510 A JP2019549510 A JP 2019549510A JP 7181886 B2 JP7181886 B2 JP 7181886B2
Authority
JP
Japan
Prior art keywords
amino acid
fusion protein
group
polypeptide
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019549510A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020509761A5 (https=
JP2020509761A (ja
Inventor
チェン・チャオ
リン・シューシャン
リィ・ユィ
チェン・シャオフォン
リウ・リアン
フゥ・ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of JP2020509761A publication Critical patent/JP2020509761A/ja
Publication of JP2020509761A5 publication Critical patent/JP2020509761A5/ja
Application granted granted Critical
Publication of JP7181886B2 publication Critical patent/JP7181886B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019549510A 2017-03-14 2018-03-14 免疫グロブリンのＦｃ部分を含む二重標的融合タンパク質 Active JP7181886B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201710148158 2017-03-14
CN201710148158.7 2017-03-14
CN201810129427.X 2018-02-08
CN201810129427 2018-02-08
PCT/CN2018/078925 WO2018166461A1 (en) 2017-03-14 2018-03-14 Dual-target fusion proteins comprising the fc portion of an immunoglobulin

Publications (3)

Publication Number Publication Date
JP2020509761A JP2020509761A (ja) 2020-04-02
JP2020509761A5 JP2020509761A5 (https=) 2020-11-19
JP7181886B2 true JP7181886B2 (ja) 2022-12-01

Family

ID=63521973

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019549510A Active JP7181886B2 (ja) 2017-03-14 2018-03-14 免疫グロブリンのＦｃ部分を含む二重標的融合タンパク質

Country Status (6)

Country Link
US (2) US12145974B2 (https=)
EP (2) EP4470551A3 (https=)
JP (1) JP7181886B2 (https=)
CN (1) CN108570109B (https=)
ES (1) ES3014984T3 (https=)
WO (1) WO2018166461A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102670157B1 (ko) 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
KR102668200B1 (ko) 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
AU2017358289C1 (en) 2016-11-10 2025-05-08 Yuhan Corporation Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
CN110709520B (zh) 2017-04-21 2024-04-05 株式会社柳韩洋行 用于产生双功能蛋白质及其衍生物的方法
AU2019218147B2 (en) * 2018-02-08 2023-06-08 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
CN111273019A (zh) * 2018-12-04 2020-06-12 山东博安生物技术有限公司 一种杜拉鲁肽elisa检测方法
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
CN111662373B (zh) * 2019-03-05 2024-05-14 广东东阳光药业股份有限公司 一种多肽分子及其应用
CN114853908B (zh) * 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
CN110357969B (zh) * 2019-05-27 2022-03-08 北京志道生物科技有限公司 一种GLP1-EGFa异源二聚体蛋白、功能及方法
CN114230663B (zh) * 2019-05-30 2022-09-27 广东东阳光药业有限公司 TrkA的抗体及其应用
CN112279920B (zh) * 2019-07-25 2024-01-16 安源医药科技（上海）有限公司 FGF21 Fc融合蛋白、GLP-1 Fc融合蛋白及它们的组合治疗剂和用途
CN115322794B (zh) 2020-01-11 2025-09-19 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
CN111122880B (zh) * 2020-02-14 2023-08-15 烟台大学 一种杜拉鲁肽的竞争elisa的检测方法及其试剂盒
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
WO2022002408A1 (en) * 2020-07-02 2022-01-06 Sanofi Glp-1r agonist / fgf21 fusion proteins
BR112023003310A2 (pt) * 2020-08-24 2023-05-02 Univ Pennsylvania Vetores virais que codificam fusões de agonistas do receptor de glp-1 e usos dos mesmos no tratamento de doenças metabólicas
US20230357411A1 (en) * 2020-11-20 2023-11-09 Sunshine Lake Pharma Co., Ltd. Humanized anti-trka antibodies and uses thereof
EP4308610A4 (en) * 2021-03-19 2025-07-16 Sunshine Lake Pharma Co Ltd USES OF FGF21 POLYPEPTIDES AND FUSION POLYPEPTIDES THEREOF
US20240350588A1 (en) * 2021-08-24 2024-10-24 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and use thereof
CN117886927A (zh) * 2022-10-14 2024-04-16 华南理工大学 一种提高血液半衰期的免疫球蛋白Fc变体及其应用
CN115991793A (zh) * 2023-01-16 2023-04-21 上海民为生物技术有限公司 具有多重活性的融合蛋白及其应用
EP4545571A4 (en) * 2023-01-18 2025-09-24 Shanghai Minwei Biotechnology Co Ltd TRIPLE ACTIVITY FUSION PROTEIN AND ITS USE
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
CN117143242B (zh) * 2023-10-30 2024-03-29 南京佰抗生物科技有限公司 抗Galectin-3蛋白的单克隆抗体组合物及应用
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity
CN118955739B (zh) * 2024-10-17 2025-02-18 华南理工大学 一种双靶点受体激动剂融合蛋白及其应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006033386A1 (ja) 2004-09-22 2006-03-30 Kirin Beer Kabushiki Kaisha 安定化されたヒトIgG4抗体
JP2008506635A (ja) 2004-05-13 2008-03-06 イーライ リリー アンド カンパニー Ｆｇｆ−２１融合タンパク質
WO2009041621A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗il-6レセプター抗体
JP2010528993A (ja) 2007-05-31 2010-08-26 ゲンマブ エー／エス 安定なＩｇＧ４抗体
WO2011056713A2 (en) 2009-11-03 2011-05-12 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for obstructive sleep apnea
WO2014014796A1 (en) 2012-07-18 2014-01-23 Eli Lilly And Company Multi-specific igg-(fab)2 constructs containing t-cell receptor constant domains
US20140056893A1 (en) 2012-08-22 2014-02-27 Eli Lilly And Company Homodimeric Proteins
JP2014527986A (ja) 2011-09-26 2014-10-23 ノバルティス アーゲー 代謝障害を処置するためのデュアル機能性タンパク質
JP2014534172A (ja) 2011-09-26 2014-12-18 ノバルティス アーゲー 代謝障害を処置するための融合タンパク質

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
GB0226787D0 (en) * 2002-11-18 2002-12-24 Qinetiq Ltd Measurement of mitotic activity
MXPA05013565A (es) 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
US20070253966A1 (en) * 2003-06-12 2007-11-01 Eli Lilly And Company Fusion Proteins
CN1890371A (zh) 2003-12-10 2007-01-03 伊莱利利公司 成纤维细胞生长因子的21突变蛋白
WO2005072769A1 (en) 2004-01-26 2005-08-11 Eli Lilly And Company Use of fgf-21 and thiazolidinedione for treating type 2 diabetes
CA2557782A1 (en) 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
EA011390B1 (ru) 2004-09-02 2009-02-27 Эли Лилли Энд Компани Мутантные белки (мутеины) фактора роста фибробластов 21
US7655627B2 (en) 2004-12-14 2010-02-02 Eli Lilly And Company Muteins of fibroblast growth factor 21
CA2693504A1 (en) * 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
EP2296690B1 (en) 2008-06-04 2016-11-30 Amgen, Inc Fgf21 mutants and uses thereof
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
EP2427207B1 (en) * 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
HRP20240135T1 (hr) 2009-05-05 2024-04-12 Amgen Inc. Fgf21 mutanti i njihove upotrebe
US20120035099A1 (en) 2009-06-11 2012-02-09 Novo Nordisk A/S Fgf21 analogues and derivatives
EP2440235A1 (en) 2009-06-11 2012-04-18 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
CN101993496B (zh) * 2009-08-20 2013-06-05 重庆富进生物医药有限公司 双重调节血糖血脂融合蛋白及其制法和用途
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
MX2014002260A (es) 2011-08-31 2014-08-18 Amgen Inc Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1.
AR087973A1 (es) 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
CA2871656A1 (en) 2012-06-11 2013-12-19 Eli Lilly And Company Fibroblast growth factor 21 variants
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
WO2014037373A1 (en) * 2012-09-07 2014-03-13 Sanofi Fusion proteins for treating a metabolic syndrome
SG11201608253XA (en) * 2014-04-04 2016-10-28 Kyowa Hakko Kirin Co Ltd Anti-death receptor 3 (dr3) antagonistic antibodies with reduced agonistic activity
JO3568B1 (ar) * 2014-09-05 2020-07-05 Janssen Pharmaceutica Nv عوامل ربط cd123 واستخداماتها
SMT202100388T1 (it) * 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
KR20160088656A (ko) 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US10844122B2 (en) * 2015-05-06 2020-11-24 Janssen Biotech, Inc. Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof
WO2017059371A1 (en) 2015-10-01 2017-04-06 Amgen Inc. Treatment of bile acid disorders
KR102668200B1 (ko) 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
KR102670157B1 (ko) 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008506635A (ja) 2004-05-13 2008-03-06 イーライ リリー アンド カンパニー Ｆｇｆ−２１融合タンパク質
WO2006033386A1 (ja) 2004-09-22 2006-03-30 Kirin Beer Kabushiki Kaisha 安定化されたヒトIgG4抗体
JP2010528993A (ja) 2007-05-31 2010-08-26 ゲンマブ エー／エス 安定なＩｇＧ４抗体
WO2009041621A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗il-6レセプター抗体
WO2011056713A2 (en) 2009-11-03 2011-05-12 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for obstructive sleep apnea
JP2014527986A (ja) 2011-09-26 2014-10-23 ノバルティス アーゲー 代謝障害を処置するためのデュアル機能性タンパク質
JP2014534172A (ja) 2011-09-26 2014-12-18 ノバルティス アーゲー 代謝障害を処置するための融合タンパク質
WO2014014796A1 (en) 2012-07-18 2014-01-23 Eli Lilly And Company Multi-specific igg-(fab)2 constructs containing t-cell receptor constant domains
US20140056893A1 (en) 2012-08-22 2014-02-27 Eli Lilly And Company Homodimeric Proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Frontires in Endocrinology，2015年11月，Vol. 6, Article 168，pp 1-9

Also Published As

Publication number Publication date
US20220127322A1 (en) 2022-04-28
EP4470551A2 (en) 2024-12-04
EP4470551A3 (en) 2025-02-26
EP3596130A1 (en) 2020-01-22
EP3596130A4 (en) 2020-12-30
CN108570109A (zh) 2018-09-25
EP3596130B1 (en) 2024-12-04
WO2018166461A1 (en) 2018-09-20
JP2020509761A (ja) 2020-04-02
US12145974B2 (en) 2024-11-19
US20250084144A1 (en) 2025-03-13
CN108570109B (zh) 2022-04-26
ES3014984T3 (en) 2025-04-28

Similar Documents

Publication Publication Date Title
JP7181886B2 (ja) 免疫グロブリンのＦｃ部分を含む二重標的融合タンパク質
TWI866897B (zh) Ｆｇｆ２１變體、融合蛋白及其應用
US7576190B2 (en) FGF-21 fusion proteins
US8809499B2 (en) Fusion protein of human fibroblast growth factor-21 and exendin-4
JP2017521377A (ja) 持続型インスリンアナログ結合体及び持続型インスリン分泌ペプチド結合体を含む糖尿病治療用組成物
CN107987170B (zh) 一种用于治疗肠道疾病的融合蛋白
AU2025223814A1 (en) A polypeptide molecule and application thereof
CN110172103B (zh) GLP-1类似物-Fc融合蛋白及其制备方法和用途
TW202245824A (zh) Fgf21多肽及其融合多肽的應用
HK40015284B (en) Dual-target fusion proteins comprising the fc portion of an immunoglobulin
HK40015284A (en) Dual-target fusion proteins comprising the fc portion of an immunoglobulin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201008

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201008

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20201211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201211

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220830

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221025

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221118

R150 Certificate of patent or registration of utility model

Ref document number: 7181886

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250